Home Bancshares, Inc. (HOMB) Forms $23.25 Double Bottom; Last Week T2 Biosystems, Inc. (TTOO) Coverage

January 2, 2018 - By Martha Paddon

Home Bancshares, Inc. (HOMB) formed double bottom with $21.16 target or 9.00% below today’s $23.25 share price. Home Bancshares, Inc. (HOMB) has $4.04B valuation. The stock decreased 0.98% or $0.23 during the last trading session, reaching $23.25. About 862,425 shares traded. Home Bancshares, Inc. (NASDAQ:Conway, AR) has 0.00% since January 2, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 9 analysts covering T2 Biosystems Inc (NASDAQ:TTOO), 5 have Buy rating, 1 Sell and 3 Hold. Therefore 56% are positive. T2 Biosystems Inc had 17 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was initiated by Canaccord Genuity on Tuesday, October 27 with “Buy”. The company was initiated on Tuesday, July 21 by BTIG Research. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, August 2 report. The company was maintained on Monday, October 30 by Canaccord Genuity. The stock has “Market Perform” rating by Leerink Swann on Thursday, November 10. The firm has “Underweight” rating given on Wednesday, March 15 by Morgan Stanley. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, November 2. The stock of T2 Biosystems, Inc. (NASDAQ:TTOO) has “Neutral” rating given on Tuesday, April 12 by Janney Capital. BTIG Research maintained the stock with “Hold” rating in Sunday, August 16 report. The rating was maintained by H.C. Wainwright on Friday, November 3 with “Buy”. See T2 Biosystems, Inc. (NASDAQ:TTOO) latest ratings:

03/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $8.0 Maintain
30/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $6.0 Maintain
18/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $8 Initiates Coverage On

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. The company has market cap of $147.60 million. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. It currently has negative earnings. The firm also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens.

The stock increased 0.49% or $0.02 during the last trading session, reaching $4.12. About 169,672 shares traded. T2 Biosystems, Inc. (NASDAQ:TTOO) has declined 60.66% since January 2, 2017 and is downtrending. It has underperformed by 77.36% the S&P500.

Analysts await Home Bancshares, Inc. (NASDAQ:Conway, AR) to report earnings on January, 18 before the open. They expect $0.34 earnings per share, down 2.86% or $0.01 from last year’s $0.35 per share. HOMB’s profit will be $59.04M for 17.10 P/E if the $0.34 EPS becomes a reality. After $0.32 actual earnings per share reported by Home Bancshares, Inc. for the previous quarter, Wall Street now forecasts 6.25% EPS growth.